Sunday, October 29, 2017

Machine learning used to surpass MELD in assessing liver disease

Machine learning used to surpass MELD in assessing liver disease

Machine learning used to surpass MELD in assessing liver disease

Before joining IBM Research in Cambridge in September 2016, I completed a three-year postdoctoral training program at Massachusetts General Hospital (MGH), working closely with Harvard faculty. Now, a collaboration between MGH and IBM Research has yielded a satisfying result - our manuscript, "The MELD-Plus: A Generalizable Prediction Risk Score in Cirrhosis," was published in PLOS ONE, a peer-reviewed online science journal.
Before joining IBM Research in Cambridge in September 2016, I completed a three-year postdoctoral training program at Massachusetts General Hospital (MGH), working closely with Harvard faculty. Now, a collaboration between MGH and IBM Research has yielded a satisfying result - our manuscript, "The MELD-Plus: A Generalizable Prediction Risk Score in Cirrhosis," was published in PLOS ONE, a peer-reviewed online science journal.

No comments:

Post a Comment